{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:18:58Z","timestamp":1787170738122,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,3,20]]},"DOI":"10.1038\/s41416-025-03328-3","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:04:28Z","timestamp":1767855868000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac\/KPNA2 axis"],"prefix":"10.1038","volume":"134","author":[{"given":"Mao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoquan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-1563","authenticated-orcid":false,"given":"Kui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"3328_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3328_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-022-01264-9","volume":"8","author":"C Liu","year":"2023","unstructured":"Liu C, Li X, Huang Q, Zhang M, Lei T, Wang F, et al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduct Target Ther. 2023;8:44.","journal-title":"Signal Transduct Target Ther"},{"key":"3328_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","volume":"24","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Toita T, Wu X, V\u00e1zquez Lim\u00f3n JC, Tarnawski R, Mandai M, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1334\u201348.","journal-title":"Lancet Oncol"},{"key":"3328_CR4","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1136\/ijgc-2024-005579","volume":"34","author":"G Caruso","year":"2024","unstructured":"Caruso G, Wagar MK, Hsu HC, Hoegl J, Rey Valzacchi GM, Fernandes A, et al. Cervical cancer: a new era. Int J Gynecol Cancer. 2024;34:1946\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"3328_CR5","doi-asserted-by":"publisher","first-page":"1351363","DOI":"10.3389\/fphar.2024.1351363","volume":"15","author":"Y Duan","year":"2024","unstructured":"Duan Y, Yang L, Wang W, Zhang P, Fu K, Li W, et al. A comprehensive bibliometric analysis (2000-2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer. Front Pharm. 2024;15:1351363.","journal-title":"Front Pharm"},{"key":"3328_CR6","doi-asserted-by":"publisher","first-page":"732266","DOI":"10.3389\/fphar.2021.732266","volume":"12","author":"RK Singla","year":"2021","unstructured":"Singla RK, Sharma P, Dubey AK, Gundamaraju R, Kumar D, Kumar S, et al. Natural product-based studies for the management of castration-resistant prostate cancer: computational to clinical studies. Front Pharm. 2021;12:732266.","journal-title":"Front Pharm"},{"key":"3328_CR7","doi-asserted-by":"publisher","first-page":"155503","DOI":"10.1016\/j.phymed.2024.155503","volume":"127","author":"D Li","year":"2024","unstructured":"Li D, Wang J, Tuo Z, Yoo KH, Yu Q, Miyamoto A, et al. Natural products and derivatives in renal, urothelial and testicular cancers: targeting signaling pathways and therapeutic potential. Phytomedicine. 2024;127:155503.","journal-title":"Phytomedicine"},{"key":"3328_CR8","doi-asserted-by":"publisher","first-page":"155600","DOI":"10.1016\/j.phymed.2024.155600","volume":"129","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wu Y, Li Y, Li S, Liu J, Yang X, et al. Natural products and derivatives for breast cancer treatment: From drug discovery to molecular mechanism. Phytomedicine. 2024;129:155600.","journal-title":"Phytomedicine"},{"key":"3328_CR9","doi-asserted-by":"crossref","unstructured":"Dong L, He J, Luo L, Wang K. Targeting the interplay of autophagy and ROS for cancer therapy: an updated overview on phytochemicals. Pharmaceuticals, 2023;16.","DOI":"10.3390\/ph16010092"},{"key":"3328_CR10","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1248\/cpb.34.3974","volume":"34","author":"R Kasai","year":"1986","unstructured":"Kasai R, Miyakoshi M, Matsumoto K, Nie RL, Zhou J, Morita T, et al. Tubeimoside I, a new cyclic bisdesmoside from Chinese cucurbitaceous folk medicine \u201ctu bei mu\u201d, a tuber of Bolbostemma paniculatum. Chem Pharm Bull. 1986;34:3974\u20137.","journal-title":"Chem Pharm Bull"},{"key":"3328_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-2006-959459","volume":"60","author":"L Yu","year":"1994","unstructured":"Yu L, Ma R, Wang Y, Nishino H. Potent anti-tumor activity and low toxicity of tubeimoside 1 isolated from Bolbostemma paniculatum. Planta Med. 1994;60:204\u20138.","journal-title":"Planta Med"},{"key":"3328_CR12","first-page":"535","volume":"40","author":"WJ Chen","year":"2012","unstructured":"Chen WJ, Yu C, Yang Z, He JL, Yin J, Liu HZ, et al. Tubeimoside-1 induces G2\/M phase arrest and apoptosis in SKOV-3 cells through increase of intracellular Ca\u00b2\u207a and caspase-dependent signaling pathways. Int J Oncol. 2012;40:535\u201343.","journal-title":"Int J Oncol"},{"key":"3328_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/aps.2016.34","volume":"37","author":"JB Yang","year":"2016","unstructured":"Yang JB, Khan M, He YY, Yao M, Li YM, Gao HW, et al. Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0\/G1 phase arrest in human prostate carcinoma cells in vitro. Acta Pharm Sin. 2016;37:950\u201362.","journal-title":"Acta Pharm Sin"},{"key":"3328_CR14","first-page":"579","volume":"28","author":"P Huang","year":"2011","unstructured":"Huang P, Yu C, Liu XQ, Ding YB, Wang YX, He JL. Cytotoxicity of tubeimoside I in human choriocarcinoma JEG-3 cells by induction of cytochrome c release and apoptosis via the mitochondrial-related signaling pathway. Int J Mol Med. 2011;28:579\u201387.","journal-title":"Int J Mol Med"},{"key":"3328_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02915-x","volume":"11","author":"K Wang","year":"2020","unstructured":"Wang K, Zhan Y, Chen B, Lu Y, Yin T, Zhou S, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020;11:708.","journal-title":"Cell Death Dis"},{"key":"3328_CR16","first-page":"303","volume":"8","author":"G Jia","year":"2015","unstructured":"Jia G, Wang Q, Wang R, Deng D, Xue L, Shao N, et al. Tubeimoside-1 induces glioma apoptosis through regulation of Bax\/Bcl-2 and the ROS\/Cytochrome C\/Caspase-3 pathway. Onco Targets Ther. 2015;8:303\u201311.","journal-title":"Onco Targets Ther"},{"key":"3328_CR17","doi-asserted-by":"publisher","first-page":"154016","DOI":"10.1016\/j.phymed.2022.154016","volume":"99","author":"Q Tang","year":"2022","unstructured":"Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, et al. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K\/Akt\/mTOR\/NF-\u03baB-mediated signaling pathway. Phytomedicine. 2022;99:154016.","journal-title":"Phytomedicine"},{"key":"3328_CR18","doi-asserted-by":"publisher","first-page":"118754","DOI":"10.1016\/j.jep.2024.118754","volume":"336","author":"T Wu","year":"2025","unstructured":"Wu T, Yu Y, Tu X, Ye L, Wang J, Xie C, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025;336:118754.","journal-title":"J Ethnopharmacol"},{"key":"3328_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1151-3","volume":"9","author":"X Feng","year":"2018","unstructured":"Feng X, Zhou J, Li J, Hou X, Li L, Chen Y, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function. Cell Death Dis. 2018;9:1117.","journal-title":"Cell Death Dis"},{"key":"3328_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13046-019-1355-0","volume":"38","author":"J Yan","year":"2019","unstructured":"Yan J, Dou X, Zhou J, Xiong Y, Mo L, Li L, et al. Tubeimoside-I sensitizes colorectal cancer cells to chemotherapy by inducing ROS-mediated impaired autophagolysosomes accumulation. J Exp Clin Cancer Res. 2019;38:353.","journal-title":"J Exp Clin Cancer Res"},{"key":"3328_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30\u20139.","journal-title":"J Clin Invest"},{"key":"3328_CR22","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/bph.13961","volume":"174","author":"W Yu","year":"2017","unstructured":"Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, et al. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Br J Pharm. 2017;174:3608\u201322.","journal-title":"Br J Pharm"},{"key":"3328_CR23","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","volume":"26","author":"XJ Yang","year":"2007","unstructured":"Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26:5310\u20138.","journal-title":"Oncogene"},{"key":"3328_CR24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-20-2828","volume":"81","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Jin X, Ma J, Ding D, Huang Z, Sheng H, et al. HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4\/6 inhibitor resistance in cancer. Cancer Res. 2021;81:1486\u201399.","journal-title":"Cancer Res"},{"key":"3328_CR25","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/0008-5472.CAN-21-4362","volume":"82","author":"P Pan","year":"2022","unstructured":"Pan P, Qin G, Wang B, Yu H, Chen J, Liu J, et al. HDAC5 loss enhances phospholipid-derived arachidonic acid generation and confers sensitivity to cPLA2 inhibition in pancreatic cancer. Cancer Res. 2022;82:4542\u201354.","journal-title":"Cancer Res"},{"key":"3328_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.233","volume":"10","author":"B Hu","year":"2020","unstructured":"Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, et al. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-\u03baB oncogenic signaling. Clin Transl Med. 2020;10:e233.","journal-title":"Clin Transl Med"},{"key":"3328_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41416-023-02341-8","volume":"129","author":"S Sharma","year":"2023","unstructured":"Sharma S, Tyagi W, Tamang R, Das S. HDAC5 modulates SATB1 transcriptional activity to promote lung adenocarcinoma. Br J Cancer. 2023;129:586\u2013600.","journal-title":"Br J Cancer"},{"key":"3328_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41416-019-0625-0","volume":"121","author":"Y Xue","year":"2019","unstructured":"Xue Y, Lian W, Zhi J, Yang W, Li Q, Guo X, et al. HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer. Br J Cancer. 2019;121:1039\u201349.","journal-title":"Br J Cancer"},{"key":"3328_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41392-021-00714-0","volume":"6","author":"J Zhao","year":"2021","unstructured":"Zhao J, Bai H, Li X, Yan J, Zou G, Wang L, et al. Glucose-sensitive acetylation of Seryl tRNA synthetase regulates lipid synthesis in breast cancer. Signal Transduct Target Ther. 2021;6:303.","journal-title":"Signal Transduct Target Ther"},{"key":"3328_CR30","doi-asserted-by":"publisher","first-page":"W26","DOI":"10.1093\/nar\/gku477","volume":"42","author":"J Nickel","year":"2014","unstructured":"Nickel J, Gohlke BO, Erehman J, Banerjee P, Rong WW, Goede A, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42:W26\u201331.","journal-title":"Nucleic Acids Res"},{"key":"3328_CR31","doi-asserted-by":"publisher","first-page":"D1328","DOI":"10.1093\/nar\/gkae883","volume":"53","author":"AP Davis","year":"2025","unstructured":"Davis AP, Wiegers TC, Sciaky D, Barkalow F, Strong M, Wyatt B, et al. Comparative Toxicogenomics Database\u2019s 20th anniversary: update 2025. Nucleic Acids Res. 2025;53:D1328\u2013d1334.","journal-title":"Nucleic Acids Res"},{"key":"3328_CR32","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u2013d646.","journal-title":"Nucleic Acids Res"},{"key":"3328_CR33","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"3328_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8:S11.","journal-title":"BMC Syst Biol"},{"key":"3328_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"3328_CR36","doi-asserted-by":"publisher","first-page":"607757","DOI":"10.3389\/fcell.2020.607757","volume":"8","author":"J Du","year":"2020","unstructured":"Du J, Dong Z, Tan L, Tan M, Zhang F, Zhang K, et al. Tubeimoside I inhibits cell proliferation and induces a partly disrupted and cytoprotective autophagy through rapidly hyperactivation of MEK1\/2-ERK1\/2 cascade via promoting PTP1B in melanoma. Front Cell Dev Biol. 2020;8:607757.","journal-title":"Front Cell Dev Biol"},{"key":"3328_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u20137.","journal-title":"Science"},{"key":"3328_CR38","doi-asserted-by":"publisher","first-page":"107446","DOI":"10.1016\/j.biotechadv.2019.107446","volume":"37","author":"RP Chen","year":"2019","unstructured":"Chen RP, Gaynor AS, Chen W. Synthetic biology approaches for targeted protein degradation. Biotechnol Adv. 2019;37:107446.","journal-title":"Biotechnol Adv"},{"key":"3328_CR39","doi-asserted-by":"publisher","first-page":"661620","DOI":"10.3389\/fonc.2021.661620","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang J, Gong C, Ke Q, Fang Z, Chen X, Ye M, et al. Insights into the function and clinical application of HDAC5 in cancer management. Front Oncol. 2021;11:661620.","journal-title":"Front Oncol"},{"key":"3328_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/jbmr.2381","volume":"30","author":"MN Wein","year":"2015","unstructured":"Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P, et al. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Min Res. 2015;30:400\u201311.","journal-title":"J Bone Min Res"},{"key":"3328_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tcb.2018.12.006","volume":"29","author":"MI Vaquero-Sedas","year":"2019","unstructured":"Vaquero-Sedas MI, Vega-Palas M. Targeting cancer through the epigenetic features of telomeric regions. Trends Cell Biol. 2019;29:281\u201390.","journal-title":"Trends Cell Biol"},{"key":"3328_CR42","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ajpath.2021.08.010","volume":"191","author":"YC Liang","year":"2021","unstructured":"Liang YC, Su Q, Liu YJ, Xiao H, Yin HZ. Centromere protein A (CENPA) regulates metabolic reprogramming in the colon cancer cells by transcriptionally activating karyopherin subunit alpha 2 (KPNA2). Am J Pathol. 2021;191:2117\u201332.","journal-title":"Am J Pathol"},{"key":"3328_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejmech.2018.11.001","volume":"162","author":"MS Islam","year":"2019","unstructured":"Islam MS, Wang C, Zheng J, Paudyal N, Zhu Y, Sun H. The potential role of tubeimosides in cancer prevention and treatment. Eur J Med Chem. 2019;162:109\u201321.","journal-title":"Eur J Med Chem"},{"key":"3328_CR44","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1007\/s00210-023-02855-1","volume":"397","author":"D Hu","year":"2024","unstructured":"Hu D, Cui L, Zhang S, He S, Zhuo Y, Li D, et al. Antitumor effect of tubeimoside-I on murine colorectal cancers through PKM2-dependent pyroptosis and immunomodulation. Naunyn Schmiedebergs Arch Pharm. 2024;397:4069\u201387.","journal-title":"Naunyn Schmiedebergs Arch Pharm"},{"key":"3328_CR45","first-page":"4327","volume":"17","author":"H Shi","year":"2018","unstructured":"Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, et al. Antitumor effects of Tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A\/VEGFR-2\/ERK signaling pathway. Mol Med Rep. 2018;17:4327\u201336.","journal-title":"Mol Med Rep"},{"key":"3328_CR46","doi-asserted-by":"crossref","unstructured":"Cao, J., E. Zhao, Q. Zhu, J. Ji, Z. Wei, B. Xu, et al., Tubeimoside-1 inhibits glioblastoma growth, migration, and invasion via inducing ubiquitylation of MET. Cells, 2019;8.","DOI":"10.3390\/cells8080774"},{"key":"3328_CR47","first-page":"12517","volume":"8","author":"Q Bian","year":"2015","unstructured":"Bian Q, Liu P, Gu J, Song B. Tubeimoside-1 inhibits the growth and invasion of colorectal cancer cells through the Wnt\/\u03b2-catenin signaling pathway. Int J Clin Exp Pathol. 2015;8:12517\u201324.","journal-title":"Int J Clin Exp Pathol"},{"key":"3328_CR48","doi-asserted-by":"publisher","first-page":"17335","DOI":"10.1073\/pnas.0706487104","volume":"104","author":"A Lahm","year":"2007","unstructured":"Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA. 2007;104:17335\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3328_CR49","doi-asserted-by":"publisher","first-page":"108190","DOI":"10.1016\/j.pharmthera.2022.108190","volume":"238","author":"C Brancolini","year":"2022","unstructured":"Brancolini C, Gagliano T, Minisini M. HDACs and the epigenetic plasticity of cancer cells: Target the complexity. Pharm Ther. 2022;238:108190.","journal-title":"Pharm Ther"},{"key":"3328_CR50","doi-asserted-by":"publisher","first-page":"153303382110559","DOI":"10.1177\/15330338211055948","volume":"20","author":"H Wang","year":"2021","unstructured":"Wang H, Xiao R, Yang B. MiR-101-3p suppresses progression of cervical squamous cell carcinoma by targeting and down-regulating KPNA2. Technol Cancer Res Treat. 2021;20:15330338211055948.","journal-title":"Technol Cancer Res Treat"},{"key":"3328_CR51","doi-asserted-by":"publisher","first-page":"e170223213775","DOI":"10.2174\/1874467216666230217151946","volume":"17","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Feng K, Yu Y, Lv Y. Hsa_Circ_0000021 Sponges miR-3940-3p\/KPNA2 expression to promote cervical cancer progression. Curr Mol Pharm. 2024;17:e170223213775.","journal-title":"Curr Mol Pharm"},{"key":"3328_CR52","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41388-021-02116-6","volume":"41","author":"F Han","year":"2022","unstructured":"Han F, Zhang L, Liao S, Zhang Y, Qian L, Hou F, et al. The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis. Oncogene. 2022;41:657\u201370.","journal-title":"Oncogene"},{"key":"3328_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-018-0861-9","volume":"37","author":"J Li","year":"2018","unstructured":"Li J, Liu Q, Liu Z, Xia Q, Zhang Z, Zhang R, et al. KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc. J Exp Clin Cancer Res. 2018;37:194.","journal-title":"J Exp Clin Cancer Res"},{"key":"3328_CR54","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41388-018-0494-7","volume":"38","author":"S Xiang","year":"2019","unstructured":"Xiang S, Wang Z, Ye Y, Zhang F, Li H, Yang Y, et al. E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. Oncogene. 2019;38:1269\u201381.","journal-title":"Oncogene"},{"key":"3328_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04449-2","volume":"12","author":"T Chen","year":"2021","unstructured":"Chen T, Liu R, Niu Y, Mo H, Wang H, Lu Y, et al. HIF-1\u03b1-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p\/KPNA2\/AKT pathway. Cell Death Dis. 2021;12:1152.","journal-title":"Cell Death Dis"},{"key":"3328_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41420-022-00844-6","volume":"8","author":"M Du","year":"2022","unstructured":"Du M, Peng Y, Li Y, Sun W, Zhu H, Wu J, et al. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell Death Discov. 2022;8:53.","journal-title":"Cell Death Discov"},{"key":"3328_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36708-5","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Luo L, Fu S, Wang M, Wang Z, Dong L, et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat Commun. 2023;14:1011.","journal-title":"Nat Commun"},{"key":"3328_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49087-2","volume":"15","author":"L Luo","year":"2024","unstructured":"Luo L, Wu X, Fan J, Dong L, Wang M, Zeng Y, et al. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma. Nat Commun. 2024;15:4790.","journal-title":"Nat Commun"},{"key":"3328_CR59","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1080\/15548627.2023.2239042","volume":"19","author":"K Wang","year":"2023","unstructured":"Wang K, Fu S, Dong L, Zhang D, Wang M, Wu X, et al. Periplocin suppresses the growth of colorectal cancer cells by triggering LGALS3 (galectin 3)-mediated lysophagy. Autophagy. 2023;19:3132\u201350.","journal-title":"Autophagy"},{"key":"3328_CR60","doi-asserted-by":"crossref","unstructured":"Wu, X., L. Luo, M. Wang, L. Dong, J. Fan, Y. Zeng, et al., PRDX6 prevents NNMT ubiquitination and degradation as a nonenzymatic mechanism to promote ovarian cancer progression. Adv Sci 2025;p.e2416484.","DOI":"10.1002\/advs.202416484"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03328-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:01:51Z","timestamp":1772647311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,20]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03328-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}